COMP <GO>
GELS vs PCSA // EV/EBITDA & P/E VALUATION
Gelteq Limited (NASDAQ) VS. Processa Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: GELS 1
— PCSA 1
■ METRIC PARITY
LAST: $0.51 (+5.11%) • MKT CAP: $5.4M
valuation
—
LAST: $1.89 (+2.16%) • MKT CAP: $5.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GELS VS. PCSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GELS | PCSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.2 | 55.7 | -7.55 | PCSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.4M | $5.3M | $131.1K | GELS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GELS REV | PCSA REV | GELS GROSS % | PCSA GROSS % | GELS FCF | PCSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$11.4M |
| FY 2024 | — | $0 | — | — | — | -$11.2M |
| FY 2023 | — | $0 | — | — | — | -$8.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GELS // BETA —
PCSA // BETA —